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Abstract
Background—Intradermal administration of fractional inactivated poliovirus vaccine (fIPV) is a 
dose-sparing alternative to intramuscular full dose. We assessed the recommendation of two fIPV 
doses or one IPV dose for routine immunization, and a fIPV booster dose for outbreak response.
Methods—We conducted an open-label, randomized, controlled, inequality, non-inferiority trial 
in two Dhaka clinics, Bangladesh. Healthy infants were randomized at 6 weeks to one of four 
arms: (A) IPV at 14 weeks and IPV at 22 weeks (booster); (B) IPV at 14 weeks and fIPV booster; 
(C) IPV at 6 weeks and fIPV booster; or (D) fIPV at 6+14 weeks and fIPV booster. Vaccines were 
administered by needle-syringe, with intradermal adapter for fIPV. Vaccine response 
(seroconversion from seronegative (<1:8) at baseline to seropositive (≥1:8) or four-fold increase in 
reciprocal antibody titers adjusted for maternal antibody decay) to types 1, 2, and 3 at 22 weeks 
(routine immunization) and 26 weeks (outbreak response) was assessed in the intention-to-treat 
population. Non-inferiority margin was 12·5%. (Registered at ClinicalTrials.gov, number 
NCT02847026).
Findings—From September 1, 2016 to May 2, 2017, 1,076 participants were assigned to Arms A 
(n=271), B (n=267), C (n=268), and D (n=270). Vaccine response at 22 weeks to two doses of 
fIPV was significantly higher (p<0.0001) than one dose of IPV (Arm D versus A/B) for type 1 
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[212 (79%, 95%CI: 73%−83%) versus 305 (57%, 95%CI: 53%−61%)], type 2 [173 (64%, 95%CI: 
58%−70%) versus 249 (46%, 95%CI: 42%−51%)], and type 3 [196 (73%, 95%CI: 67%−78%) 
versus 196 (36%, 95%CI: 33%−41%)]. At 26 weeks, fIPV booster was non-inferior to IPV (Arm 
B versus A) to types 1 (−1·1%, 90%CI: −2·2% - −0·1%), type 2 (0·4%, 90%CI: −2·2% - 1·4%), 
and type 3 (−1·5%, 90%CI: −3·2% - −0·2%). Of 129 adverse events, 21 were serious including one 
death; none were attributed to IPV/fIPV.
Interpretation—fIPV is an effective dose-sparing strategy for routine immunization and 
outbreak response.
Funding—U.S. Centers for Disease Control and Prevention
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Introduction
After type 2 wild poliovirus was certified eradicated in 2015, the Global Polio Eradication 
Initiative (GPEI) conducted a globally synchronized withdrawal of oral poliovirus vaccine 
(OPV) type 2 in April 2016 by replacing trivalent OPV (tOPV; types 1, 2, and 3) with 
bivalent OPV (bOPV; types 1 and 3).1 Cessation of routine use of OPV2 was essential to 
mitigate risk that the live, attenuated type 2 vaccine virus would continue circulation in 
under-immunized populations and genetically revert and reacquire neurovirulence thereby 
causing paralysis.2 To offset the gap in type 2 immunity, the World Health Organization 
(WHO) Strategic Advisory Group of Experts on Immunization (SAGE) recommended all 
OPV-using countries to introduce one dose of inactivated poliovirus vaccine (IPV; types 1, 2, 
and 3) at age 14 weeks or later prior to OPV2 cessation.3 Depending on the age of 
administration, vaccine response to one IPV dose was between 34–77% for type 2; evidence 
of priming among seronegative children was such that the cumulative vaccine response 
(vaccine response plus priming) to one dose of IPV was ≥90% [Anand, personal 
communication].4–6 In the event of a type 2 outbreak, a dose of type 2 containing vaccine in 
a population that had received at least one dose of IPV would rapidly induce protective 
levels of immunity against paralysis. However, IPV manufacturers were unable to meet the 
global supply demand and 49 countries either delayed IPV introduction or experienced a 
stock-out after introduction.7
Intradermal administration of fractional dose of IPV (fIPV) has been investigated since 1953 
and studies in the 1990’s demonstrated that a one-fifth fIPV dose (0.1ml) of the enhanced-
potency IPV (i.e., current IPV formulation, 0.5ml) was immunogenic.8–12 Since the 2008 
World Health Assembly, fIPV has been further explored as a cost-saving option for countries 
due to the substantially higher cost of IPV compared with OPV;13 however, fIPV is also 
being pursued as a dose-sparing option in light of the limited IPV supply.
In 2016, SAGE encouraged countries to evaluate the cost-benefits, trade-offs, and 
programmatic feasibility of providing two fIPV doses at ages 6 and 14 weeks as an 
alternative to one IPV dose.14 It was inferred that this schedule would provide a higher 
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vaccine response based on comparisons of study arm(s) from multiple clinical trials4–6,15–20 
but no clinical trial has directly compared these two options. As of September 2018, this 
schedule has been introduced in Bangladesh, Cuba, Ecuador, India, Nepal, and Sri Lanka.
The global IPV shortage also has implications for outbreak response activities. GPEI had 
proposed that response activities include IPV as a booster to quickly improve immunity, 
especially to type 2. IPV supply shortages have led countries to stretch supplies by using 
fIPV when responding to type 2 poliovirus events.21,22 Based on studies in adults and older 
children previously vaccinated with OPV,12,14 SAGE recommended in October 2016 that 
fIPV be used in response campaigns if IPV was deemed necessary. No studies have 
compared type 2 immunogenicity of a fIPV booster instead of IPV among OPV-naïve 
children vaccinated with a single IPV dose.
We conducted a clinical trial among OPV-naïve infants to compare the immunogenicity of 
two fIPV doses at ages 6 and 14 weeks to one dose of IPV at age 14 weeks. The use of IPV 
in OPV-naïve infants also allowed us to investigate the immunogenicity of two doses of IPV 
in comparison with three doses of fIPV to inform deliberations of vaccination schedules 
after OPV use is discontinued globally. To inform policies related to fIPV use in outbreak 
settings, we compared the immunogenicity of an IPV booster with a fIPV booster, both 
given to infants who received IPV at 14 weeks of age. We also assessed immunogenicity of a 
fIPV booster administered to infants who received IPV at 14 weeks of age in comparison 
with IPV given at 6 weeks, or fIPV given at 6 and 14 weeks.
Methods
Study design and participants
We conducted a randomized, controlled, parallel, open-label, inequality, non-inferiority trial 
in Mirpur in urban Dhaka, Bangladesh. A second site was established shortly thereafter in 
the Mohakahli area of Dhaka to increase participant enrollment. Bangladesh withdrew 
OPV2 use in April 2016. The study included an independent evaluation of immunogenicity 
to oral rotavirus vaccines; for simplicity, details and results presented in this paper focus 
only on the poliovirus component as there is no reported interference between IPV and oral 
rotavirus vaccines. The study and amendments were approved by icddr,b’s Institutional 
Review Board. Study and amendments were shared with CDC but deferred to icddr,b’s IRB; 
CDC staff had no interaction with human subjects nor access to personally identifiable 
information.
Field workers identified expectant mothers within assigned communities and interested 
parents were invited to participate. Infants aged 6 weeks (42–48 days) were eligible if they 
were full-term (>37 weeks) singleton births and would remain in the area for the study 
duration. Written informed consent was obtained from parents. Infants were excluded if they 
had evidence or indication of a medical condition that contraindicated venipuncture or 
parenteral administration of IPV; chronic medical condition identified by a study medical 
officer (not including stunting or wasting); severe illness that required hospital admission; 
vomiting or intolerance to liquids in the 24 hours prior to enrollment; receipt of any 
poliovirus or rotavirus vaccine prior to enrollment; any known allergies or sensitivity to 
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polio or rotavirus vaccines or contents; or history of intussusception, intestinal 
malformation, or abdominal surgery. Parents could withdraw consent for participation at any 
time. Study staff withdrew participants if poliovirus or rotavirus vaccine was received 
outside the study; identified a medical condition in which continued participation posed a 
risk; used immunosuppressive medications; or were unable to obtain blood during the first 
visit.
Randomization and masking
Participants were randomly allocated (1:1:1:1) to one of four study arms, each arm 
representing a potential routine immunization schedule (i.e., primary series) and a booster 
dose. The four arms were: A) IPV at age 14 weeks and IPV booster at age 22 weeks 
(IPV14+IPV); B) IPV at age 14 weeks and fIPV booster at age 22 weeks (IPV14+fIPV); C) 
IPV at age 6 weeks and fIPV booster at age 22 weeks (IPV6+fIPV); and D) fIPV at age 6 
and 14 weeks and fIPV booster at age 22 weeks (fIPV6/14+fIPV). At each study clinic, 
block randomization was used with block sizes of 8, 16, 24, and 32. Investigators with no 
participant engagement generated the randomization sequence using R (R foundation, 
version 3.2.1) and concealed randomization assignment in sequentially numbered, sealed, 
opaque envelopes. Study clinic staff had no a-priori knowledge of the randomization 
scheme; arm assignment was unmasked to parents and study clinic staff when envelopes 
were opened. Only laboratory staff remained blinded to assignment during and after the trial.
Procedures
Upon enrollment, staff obtained the infant’s clinical history (i.e., breastfeeding, previous 
vaccination, and health status), conducted a physical examination (including temperature, 
weight, and length), collected a sample of blood, administered IPV or fIPV (IPV6+fIPV and 
fIPV6/14+fIPV arms only), and monitored infants for 30 minutes for any systemic or site of 
injection adverse events. Weight and length were measured twice using an electronic scale 
with precision to 100 grams and a measuring board with precision to 1 mm, respectively. 
The mean of the two measurements were used to assess whether participants had evidence of 
wasting (reduced weight for age) or stunting (reduced length for age) using the child-growth 
standard curves from WHO’s Multicenter Growth Reference Study.23 Wasting or stunting 
was present if participant measurements were more than two standard deviations below the 
mean of the reference population. Participants returned for study clinic visits at ages 14 
weeks, 22 weeks, 23 weeks, and 26 weeks to complete polio-related activities; visits at age 
10 and 18 weeks were also conducted for rotavirus vaccine-related activities. At each visit, 
staff again collected information on the participant’s clinical history, conducted physical 
examinations, collected a sample of blood (22, 23, and 26 weeks), administered IPV or fIPV 
(14 and 22 weeks), and monitored for adverse events. All blood samples were collected prior 
to study vaccine administration.
The IPV/fIPV used in this trial was manufactured by Sanofi Pasteur (Lyon, France) and each 
full dose contained type 1 (40 D-antigen unit of the Mahoney strain), type 2 (8 D-antigen 
unit of the MEF-1 strain), and type 3 (32 D-antigen unit of the Saukett strain). IPV was only 
available for procurement as a pre-filled syringe and was used in accordance with the 
manufacturer’s instructions when administered as an intramuscular full dose (0·5ml). For 
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fIPV administration, the contents of the pre-filled IPV syringe were transferred into a sterile 
vial and 0·1ml of vaccine was withdrawn using the HelmJect auto-disable syringe 0·1ml 
27Gx1/2”. The Helms intradermal adapter was then affixed to the needle-syringe for 
intradermal administration. Sanavita (formerly Helm Medical GmbH) donated the needle-
syringe and intradermal adapter as a blister pack. IPV and fIPV were administered on the 
outer, upper right thigh of participants. Participants also received all routine immunization 
vaccines (except polio) according to the schedule of the Expanded Programme on 
Immunization of the Bangladesh Ministry of Health and Family Welfare. This included 
pentavalent (diphtheria, pertussis, tetanus, Hepatitis B, Haemophilus influenzae type B) and 
the pneumococcal conjugate vaccine (PCV, Streptococcus pneumoniae). Upon participation 
completion, infants in Arms C and D received one dose of IPV and all infants received three 
doses of bOPV at four-week intervals beginning at 26 weeks of age to ensure compliance 
with national guidelines for polio vaccination. All vaccines remained in cold chain per 
manufacturer’s recommendations.
Blood samples (1 or 1.5 ml, depending on poliovirus and rotavirus testing needs) were 
collected prior to study vaccination by venipuncture and transported to icddr,b’s laboratory 
by the end of the day; samples were stored and transported at 2–8°C. Samples were 
centrifuged within 24 hours of collection and serum were aliquoted for testing (stored at 
−20°C) and storage (stored at −70°C). Upon completion of all study activities, sera were 
sent to the Centers for Disease Control and Prevention laboratory in Atlanta, GA, USA, for 
testing. The polio microneutralization assay was used to measure antibody titers to 
poliovirus types 1, 2, and 3 and the upper limit of detection was ≥1448.24
Outcomes
The primary outcome was vaccine response measured at two time points: 22 weeks of age 
(8–16 weeks after the last primary series vaccination); and 26 weeks of age (four weeks after 
the booster dose at 22 weeks of age). Vaccine response was defined as seroconversion from 
seronegative (<1:8) at baseline (i.e., 6 weeks of age) to seropositive (≥1:8) after vaccination, 
or a four-fold rise in antibody titers between baseline and post-vaccination adjusted for the 
exponential decay of maternal antibodies assuming a half-life of 28 days. Vaccine response 
at 22 weeks of age (i.e., vaccine response to primary series) was used to assess any 
differences in immunogenicity of two doses of fIPV in comparison with one dose of IPV 
(Arm D vs A/B). Vaccine response at 26 weeks of age (i.e., vaccine response to booster) was 
used to assess: 1) non-inferiority of a fIPV booster in comparison with an IPV booster (Arm 
B vs A); 2) differences in immunogenicity of fIPV booster when given after two doses of 
fIPV in comparison with one dose IPV (Arm D vs B); 3) non-inferiority of a fIPV booster 
when given after one dose of IPV at 6 weeks in comparison with IPV at 14 weeks (Arm C vs 
B); and 4) differences in immunogenicity between three fIPV doses in comparison with two 
doses of IPV (Arm D vs A).
The secondary outcomes were priming, cumulative vaccine response, and median reciprocal 
antibody titers. Priming was defined as the absence of type-specific vaccine response at 22 
weeks with subsequent evidence of response at 23 weeks. Cumulative vaccine response to 
one dose of IPV was defined as vaccine response at 22 weeks or priming response at 23 
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weeks. Assessments of priming and cumulative vaccine response were the same as 
previously noted but restricted to arms in which one dose of IPV was given in the primary 
series (i.e., no comparisons with Arm D). Median reciprocal antibody titers were calculated 
at the same time points of interest as vaccine response (22 and 26 weeks of age), priming (23 
weeks of age), and cumulative vaccine response (22 and 23 weeks of age).
Systemic and site of injection adverse events were monitored during the course of the study. 
Adverse events were defined as any illness experienced by the participant during the study 
period. Serious adverse events were defined as death, hospitalization, paralysis or severe 
disability, and anaphylaxis reaction after vaccine administration. During clinic visits, parents 
were asked about any illness since the last clinic visit and participants were monitored for 
adverse events for 30 minutes immediately after vaccination. Parents were instructed to seek 
care immediately and contact the study clinic if their infant became ill between study clinic 
visits. All adverse event reports were reviewed by the principal investigator and all serious 
adverse event reports were shared within 24 hours to icddr,b’s institutional review board, the 
Data Safety and Monitoring Board, Sanavita, and CDC.
Sample Size and Statistical Analysis
The sample size for the study was calculated to address the primary objectives. A sample 
size of 888 was calculated (222 per arm). To account for 10% of participants who would be 
seropositive with antibody titers close to the upper limit of detection at baseline and 10% 
attrition, we calculated an enrollment target of 1,144 infants (286 per arm). To assess non-
inferiority of a fIPV booster in comparison with an IPV booster among participants who 
have received one IPV, we used a conservative vaccine response estimate of 60% [Anand, 
personal communication].6 The enrollment target of 286 per arm was sufficient for non-
inferiority defined as at least a 12·5% difference in vaccine response, power of 85% with a 
one-sided α of 0·05, and evaluated at no difference between arms under the alternative 
hypothesis of non-inferiority. To evaluate differences in vaccine response among infants 
given two fIPV in comparison with one IPV, we estimated that 80% of infants would 
respond after two fIPV at 6 and 14 weeks of age and 70% of infants would respond to one 
IPV at 14 weeks of age [Anand, personal communication].4,6 An enrollment target of 286 in 
Arm D (two doses fIPV) and 572 in Arms A and B combined (after one dose IPV) was 
sufficient to obtain 80% power with two-sided α of 0·05 to detect a statistically significant 
difference in immune response of at least 12·5%.
Inequality tests were done by Fisher’s exact to evaluate differences in vaccine response, and 
differences in priming response. Non-inferiority was assessed by comparing the lower bound 
of a 90% Wald Confidence Interval (CI) to the non-inferiority margin. The Kruskal-Wallis 
test was used to assess differences in measured antibody titer distributions among responders 
between study arms. Multiple comparison correction was not applied to the analyses because 
a-priori hypotheses were investigated at different outcome endpoints. Post-hoc analyses 
were performed to assess the influence of maternal antibodies. Reverse cumulative 
distribution function curves were used to visualize differences in antibody titers among 
responders with the y-axis denoting the proportion of infants with antibody titers at the 
corresponding x-axis and greater. Descriptive analyses (percentages and medians) were 
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performed for baseline characteristics, adverse events, characteristics of fIPV injections, and 
influence of maternal antibodies. The presence of poliovirus antibody titers at baseline was 
assumed to represent maternal antibodies; titers ≥64 were categorized as “high” while titers 
<64 were categorized as “low/undetectable”. Results and conclusions by intention-to-treat 
and per protocol analyses did not differ; we present results from the intention-to-treat 
analysis and include per protocol results in the appendix. Data were analyzed in SAS (Cary 
NC, Version 9.4) and R (R Foundation, Version 3.3.3). This trial is registered at 
ClinicalTrials.gov (number NCT02847026).
Role of the funding source
The sponsor of the study participated in study design, protocol development, data analysis, 
data interpretation, and manuscript development. The sponsor did not participate in data 
collection. The corresponding author had full access to all study data, except personally 
identifiable information, and had final responsibility for the decision to submit for 
publication.
Results
Of 1,221 parents approached for the study, 1,144 infants were enrolled from September 1, 
2016 to May 2, 2017 (Figure 1). The intention-to-treat analysis included 1,076 (94%) 
participants. Baseline characteristics by study arm are summarized in Table 1.
At 22 weeks of age, participants who received two fIPV (Arm D) had significantly higher 
(p<0.0001) vaccine response (Table 2A) and median antibody titers (Table 2B) for all 
serotypes than participants who received one IPV (Arms A/B). For type 1 this was 212 
participants (79%, 95%CI: 73%−83%) compared with 305 (57%, 95%CI: 53%−61%)], type 
2 was 173 participants (64%, 95%CI: 58%−70%) compared with 249 participants (46%, 
95%CI: 42%−51%)], and type 3 was 196 participants (73%, 95%CI: 67%−78%) compared 
with 196 participants (36%, 95%CI: 33%−41). Median reciprocal antibody titers among 
those with vaccine response who received two doses of fIPV was 144 (interquartile range 
(IQR): 51–455) in comparison with one dose IPV which was 23 (IQR): 14–57) for type 1, 
45 (IQR: 18–144) compared with 14 (IQR: 11–23) for type 2, and 91 (IQR: 36–455) in 
comparison with 18 (IQR: 11–57) for type 3. In assessing a potential vaccine schedule of 
two IPV (Arm A) in comparison with three fIPV (Arm D) at 26 weeks of age, there was a 
significant difference for type 1 (100% vs 98%, Table 2A). Median antibody titers among 
those with vaccine response were 3–6 fold higher among participants who received two IPV 
when compared to three fIPV (Table 2B).
Findings from the priming assessment show that participants who received IPV at 14 weeks 
of age had similar priming response (97%−100%) and cumulative vaccine response (98%
−100%) to all types irrespective of IPV (Arm A) or fIPV booster (Arm B, Table 2A). 
However, median titers were significantly higher among those who received an IPV booster 
compared with fIPV booster (Table 2B) despite high overall median titers (≥256) in both 
groups. Participants who received IPV6+fIPV booster (Arm C) had significantly lower 
priming and cumulative vaccine response to types 1 and 2 than those who received 
IPV14+fIPV booster (Arm B). Median antibody titers of priming and cumulative vaccine 
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response in the IPV6+fIPV arm was high (>724) for all types and was significantly higher 
than IPV14+fIPV (Arm B) for type 1.
Results from the booster dose analyses indicate that fIPV was non-inferior to IPV for all 
types following IPV at 14 weeks of age (Figure 2A). Vaccine response to IPV6+fIPV 
booster (Arm C) was non-inferior to IPV14+fIPV booster (Arm B) for types 1 and 3 (Figure 
2B). The lower limit of the confidence interval for the type 2 difference was 12·4%. Vaccine 
response to IPV14+fIPV booster (Arm B) and fIPV6/14+fIPV booster (Arm D) was similar 
for all serotypes (>96%). Overall, antibody titers were highest among participants in 
IPV14+IPV booster (Arm A) and lowest among participants in fIPV6/14+fIPV booster 
(Arm D, Figure 3).
A total of 129 adverse events were reported of which 21 (16%) were classified as serious 
including one death due to aspiration; none of the adverse events were attributed to use of 
the polio vaccines. The most commonly reported illnesses were respiratory infections 
(n=68), diarrhea (n=29), and dermatological conditions (i.e., cellulitis, chicken pox, scabies, 
and tinea capitis) (n=17). Other reported illnesses included conjunctivitis (n=5), oral thrush 
(n=4), respiratory and gastrointestinal co-infection (n=3), and single reports of measles and 
meningitis. All participants reported one adverse event except one participant who reported 
two.
There were 1,296 fIPV administrations during the study. The median bleb size was 8 mm 
(range: 4–11 mm) and 15 (1·2%) were ≤5 mm. There was no evidence of wetness (i.e., 
vaccine visible on the skin) among 1,267 (97·8%) injections. Of the 29 administrations with 
evidence of a small drop (28) or partial wetness (1), five (17·2%) were observed with bleb 
sizes that were small (≤5 mm).
High maternal antibody titers at baseline were associated with lower type 2 vaccine response 
at 22 weeks of age. Among participants who received IPV at age 14 weeks, 243 of 491 
(49·5%) with low/undetectable maternal antibody titers responded compared to 6 of 47 
(12·8%) with high titers. Likewise, participants who received IPV at age 6 weeks and had 
low/undetectable maternal antibody titers had higher vaccine response [70 of 245 (28·6%)] 
than those with high titers [0 of 23 (0%)]. Finally, 173 of 251 (68·9%) of participants who 
received fIPV at 6 and 14 weeks and low/undetectable maternal antibodies had vaccine 
response compared to 0 of 19 (0%) with high titers. A similar trend was not observed for 
types 1 and 3 (data not shown).
Discussion
Several important findings from our study can be used to inform the use of fIPV in routine 
immunization schedules and outbreak response. First, our study is the first to demonstrate in 
a direct comparison that two intradermal doses of fIPV at 6 and 14 weeks of age is more 
immunogenic for all types than one intramuscular dose of IPV at 14 weeks of age. Type-
specific vaccine response to two fIPV was 16–36% higher when compared to one IPV and 
antibody titers were 5–6 times as high. Type-specific response to two fIPV in our study (64–
79%) was similar to a study in Oman (69%−72%)18 but lower than a previous study in the 
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same Dhaka community of similarly aged children (81%−89%)4 and slightly older children 
in Cuba (93%−98%)5. Higher type 2 response to one dose of IPV at 14 weeks was reported 
in studies from Bangladesh (73%) [Anand, personal communication], India (69%),6 Panama 
(75%),20 and Latin American countries (80%)17 compared with our study (46%). The 
observed differences for both fIPV and IPV groups may be due to absence of secondary 
exposure to type 2 because our study was conducted after OPV2 withdrawal. Other possible 
reasons include IPV from different manufacturers, different interval between fIPV 
vaccinations,5,18 baseline maternal antibodies, and different devices used for fIPV 
administration.
Second, participants who received IPV at 14 weeks of age had ≥98% cumulative vaccine 
response to all types irrespective of receiving IPV or a fIPV booster. This high cumulative 
vaccine response is consistent with a previous study in the same community [Anand, 
personal communication] and another in India.6 Participants who received IPV at 6 weeks 
and fIPV booster had relatively high cumulative vaccine response to types 1 and 3 (>96%) 
but type 2 (88%) response was ~10% lower than those who received IPV at 14 weeks and 
fIPV booster. This finding differs from another study in this community where type 2 
cumulative response was 99% among those who received IPV at 6 weeks. However, 
secondary transmission from tOPV use during the latter study may have led to higher 
cumulative response. Another previous study in the same Dhaka community detected 14% 
vaccine response to type 2 among participants who only received bOPV.4 Moreover, an IPV 
booster was administered in that study instead of fIPV, which may have led to higher 
priming and cumulative vaccine response. Our finding suggests that a full dose IPV may be 
necessary to obtain high cumulative vaccine response if the first IPV dose is given before 14 
weeks of age.
Third, a fIPV booster is non-inferior to an IPV booster for all serotypes (<2% difference) 
when given to individuals who have received IPV at 14 weeks of age. While type 1 and 3 
responses to a fIPV booster among infants who received IPV at 6 weeks in comparison with 
IPV at 14 weeks were non-inferior, the type 2 response was interpreted as inferior because 
the lower limit of the difference (12·4%) almost reached the 12·5% non-inferiority margin. 
Due to the large programmatic implications of misinterpreting the result, we erred on the 
side of caution in our interpretation. There was no difference in vaccine response for all 
serotypes (>96%) when a fIPV booster was given to participants who received two fIPV 
compared to IPV at 14 weeks. This is the first study to assess immunogenicity of fIPV 
booster in OPV-naïve children who previously received a single IPV at 14 weeks of age or 
two fIPV doses at 6 and 14 weeks of age. The feasibility of fIPV use in campaigns was 
recently demonstrated in India and Pakistan using needle-syringe21,22 and a needle-free jet 
injector.25 All reported high vaccination coverage although issues with identifying skilled 
and well-trained vaccinators to administer intradermal injections with needle-syringe were 
noted. Devices such as the intradermal adapter used in this study and needle-free jet 
injectors may overcome these issues but immunogenicity of needle-free devices should be 
assessed if any changes to the device are made since previous immunogenicity trials as 
changes may unintentionally affect immunogenicity.
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Finally, our evaluation of a potential future schedule of two IPV doses versus three fIPV 
doses found high vaccine response (>96%) to all serotypes for both schedules. While there 
was a significant difference observed for type 1 (p=0.02), programmatically this difference 
of 98% versus 100% is not meaningful. Discussions are ongoing about the introduction of a 
second dose of IPV in preparation for OPV cessation from routine immunization programs. 
For countries that have already introduced two fIPV doses, our finding provides clinical 
evidence indicating a schedule with three fIPV doses (6, 14, and 22 weeks) would be as 
immunogenic as a schedule with two IPV doses (14 and 22 weeks). Vaccine response may 
differ depending on the age at first dose and the time interval between vaccinations.
Interference from maternal antibodies has been reported in other studies that evaluated 
immunogenicity of fIPV and IPV.18,19 We observed maternal antibody interference to type 2 
in all study arms when vaccine response was assessed after the primary series at 22 weeks; a 
similar type 2 only affect was observed in Cuba.26However, a robust type 1 response was 
observed despite similar prevalence and higher titers at baseline than type 2. Interference of 
maternal antibodies to type 1 may not have been observed due to secondary exposure to 
bOPV or another undetermined factor; the study in Cuba was conducted at a time of no 
secondary exposure to OPV.
Participants who received IPV at 6 weeks of age followed by a fIPV booster had lower levels 
of type 2 priming, cumulative vaccine response, and vaccine response to the booster 
compared to those who received IPV at 14 weeks of age. Further research on whether an 
IPV booster could close the immunity gap compared with fIPV booster would be 
informative, especially if countries are considering a schedule in which IPV is given at 6 
weeks to increase overall polio vaccination coverage or to protect against VAPP when 
followed by bOPV.
The IPV booster led to consistently higher antibody titers when compared with the fIPV 
booster; other studies reported similar findings.27–29 This finding may be explained by the 
lower antigen content in fIPV than in IPV, which did not appear to be compensated by the 
enhanced immune response expected from the introduction of the antigen in the dendritic 
cell-rich environment of the dermis. Poor intradermal administration technique is unlikely to 
explain the low response given the relatively large bleb size and minimal wetness observed 
in our study. The implication of the lower antibody titers on individual protection is unclear. 
Detectable antibody titers (>1:8) are globally recognized as protective against paralysis. 
Antibody titers decay over time; high antibody titers after primary vaccination remain above 
detectable levels for a longer period than low antibody titers suggesting a longer duration of 
protection against paralysis.30 However, evidence suggests that immunological memory may 
persist even in the absence of detectable antibody titers,31 yet whether secondary response 
could be induced fast enough to prevent paralysis is unknown.
Our study had several strengths and limitations. It was conducted among OPV-naïve infants 
that allowed us to examine the effect of a fIPV booster in those who had received IPV or 
fIPV only. Furthermore, it was conducted after OPV2 withdrawal and provides an estimate 
of type 2 response that is unaffected by secondary type 2 transmission. But bOPV is still in 
use and secondary transmission of types 1 and 3 may have led to higher observed vaccine 
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response. This is thought to be minimal for types 1 (5%) and 3 (3%) based on a recent study 
in the same population [Zaman, personal communication]. Furthermore, we believe our 
interpretations remain accurate because all study arms would have been equally affected. We 
used intradermal adapters to minimize the effect of poor injection quality on our 
interpretation of findings related to fIPV, which differs from use of needle-syringe only in 
routine immunization programs. The high percentage of good injection quality (e.g., larger 
bleb sizes and wetness in <3% of injections) may have led to higher percentages of vaccine 
response than what would be routinely observed in the field.
Our study supports SAGE’s recommendation to introduce two doses of fIPV at 6 and 14 
weeks of age in routine immunization schedules. Furthermore, it supports SAGE’s 
recommendation to use a fIPV booster as part of outbreak response efforts to rapidly 
increase immunity in children previously vaccinated with IPV or fIPV, especially for type 2 
outbreaks affecting cohorts with no exposure to OPV2. Use of fIPV in both situations serves 
as an effective dose-sparing strategy without compromising individual and population 
immunity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Panel: Research in context
Evidence before this study
In 2013, the Strategic Advisory Group of Experts on Immunization recommended 
countries introduce one dose of intramuscular inactivated poliovirus vaccine (IPV) as a 
risk mitigation strategy against the decline in type 2 immunity that would occur with the 
planned removal of type 2 in the oral poliovirus vaccine (OPV) in 2016. A global IPV 
supply shortage ensued as vaccine manufacturers were unable to meet the increased 
demand. The Strategic Advisory Group of Experts on Immunization in 2016 encouraged 
countries to assess the feasibility of introducing two intradermal doses of fractional IPV 
(fIPV) at 6 and 14 weeks of age in lieu of one dose IPV at 14 weeks of age as a means to 
stretch the limited global supply. This recommendation was based on evidence from 
indirect comparisons that suggested two fIPV doses would be more immunogenic than 
one IPV dose. They also recommended in October 2016 that if IPV was to be used in 
response activities, fIPV be used instead to rapidly protect individuals and populations 
based on studies in adults and older children who had been vaccinated with OPV.
We conducted a PubMed search to confirm the absence of data that would further inform 
the recommendations. We identified English language publications between 1 January 
1990 to 15 July 2018 using the terms “fractional inactivated poliovirus vaccine”, 
“inactivated poliovirus vaccine”, and “intradermal”. We restricted our search to clinical 
trials after 1990 when enhanced IPV (current formulation) was more commonly used. We 
selected studies that assessed vaccine response to IPV or fIPV in the absence of OPV use, 
regardless of use as part of primary vaccination series or as a booster. Trials of IPV and 
OPV that included an IPV or fIPV only arm(s) were included in our search. Recent 
review articles on fIPV were also used to confirm our search strategy. We did not identify 
any studies that directly compared two doses of fIPV at 6 and 14 weeks of age with one 
dose of IPV at 14 weeks of age.
There were no data on type 2 vaccine response to a fIPV booster in OPV-naïve children 
who previously received IPV or fIPV.
Added value of this study
This is the first study to directly compare the recommended two dose fIPV schedule at 6 
and 14 weeks of age with one dose of IPV at 14 weeks. Results indicate that two doses of 
fIPV led to higher vaccine response and antibody titers than one dose of IPV. This is also 
the first study to assess fIPV as a booster amongst OPV-naïve infants who had received 
IPV or fIPV only. Vaccine response to a fIPV booster was non-inferior to an IPV booster 
when given to infants who had received IPV at 14 weeks of age. Furthermore, a fIPV 
booster was able to elicit similar vaccine response among infants who previously received 
IPV at 14 weeks or two fIPV at 6 and 14 weeks. However, antibody titers were 
consistently higher among those who had received IPV as part of a primary series or as a 
booster.
Implication of all the available evidence
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Findings from this study directly support the Strategic Advisory Group of Experts on 
Immunization’s recommendations to use fIPV as a dose-sparing strategy for routine 
immunization schedules and outbreak response. It is vital to balance IPV use between 
these two competing priorities. Results from this study should be used to further 
encourage countries that have yet to introduce IPV in routine immunization schedules, or 
have not received additional IPV supplies since initial introduction, to introduce fIPV to 
protect their population against type 2. Furthermore, fIPV should be considered for use in 
outbreak response campaigns if IPV is to be used, permitting vaccination of five-times 
more children per IPV vial than a full dose.
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Figure 1. Trial profile, Bangladesh 2016–2017
IPV=inactivated poliovirus vaccine. fIPV=fractional inactivated poliovirus vaccine.
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Figure 2. Non-inferiority assessment of vaccine response to poliovirus types 1, 2, and 3, four 
weeks after booster vaccination
Differences in vaccine response are presented along with 90% confidence intervals around 
the estimated difference. The hashed line represents the non-inferiority margin defined at 
−12.5%. Non-inferiority is concluded if the lower bound of the 90% confidence interval falls 
to the right of the non-inferiority margin. (2A) IPV at 14 weeks and fIPV booster (Arm B) in 
comparison with IPV at 14 weeks and IPV booster (Arm A). (2B) IPV at 6 weeks and fIPV 
booster (Arm C) in comparison with IPV at 14 weeks and fIPV booster (Arm B).
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Figure 3. Reverse cumulative distribution function curves of reciprocal antibody titers to 
poliovirus types 1, 2, and 3 by study arm
(3A-3C) Proportion of participants (y-axis) with measured reciprocal antibody titers and all 
greater titers (x-axis) among vaccine responders at 22 weeks of age by poliovirus type (prior 
to booster vaccination). (3D-3F) Proportion of participants with measured reciprocal 
antibody titers and all greater titers among vaccine responders at 26 weeks of age by 
poliovirus type (four weeks after booster vaccination).
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Table 0.
Key time points for study activities by study arm
Arm
Age of participant
6 weeks 10 weeks 14 weeks 18 weeks 22 weeks 23 weeks 26 weeks
A ● IPV ● IPV ● ●
B ● IPV ● fIPV ● ●
C ● IPV ● fIPV ● ●
D ● fIPV fIPV ● fIPV ● ●
(●)indicates blood collection. IPV=inactivated poliovirus vaccines. fIPV=fractional inactivated poliovirus vaccine.
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Table 1.
Baseline characteristics of the intention-to-treat population
Baseline Characteristics
Arm A Arm B Arm C Arm D
IPV14+IPV booster IPV14+fIPV booster IPV6+fIPV booster fIPV6/14+fIPV booster
(n=271) (n=267) (n=268) (n=270)
Age (days) 44 (43–47) 44 (42–47) 44 (42–47) 44 (43–47)
Male 136 50% 128 48% 136 51% 127 47%
Mother’s education
 No formal school 48 18% 48 18% 45 17% 45 17%
 Primary 98 36% 109 41% 110 41% 92 34%
 Middle 62 23% 66 25% 63 24% 73 27%
 High 46 17% 34 13% 40 15% 45 17%
 Graduate 17 6% 10 4% 10 4% 15 6%
Exclusive breastfeeding 66 24% 65 24% 67 25% 87 32%
Wasting present 16 6% 19 7% 16 6% 18 7%
Stunting present 27 10% 43 16% 38 14% 31 11%
Type 1 poliovirus
 Seropositive 149 55% 132 49% 146 54% 140 52%
 Reciprocal titers 28 (14–91) 28 (14–114) 28 (11–114) 36 (14–144)
Type 2 poliovirus
 Seropositive 165 61% 139 52% 139 52% 149 55%
 Reciprocal titers 18 (11–36) 18 (11–36) 18 (11–45) 18 (11–36)
Type 3 poliovirus
 Seropositive 87 32% 91 34% 98 37% 81 30%
 Reciprocal titers 18 (11–45) 23 (11–57) 23 (11–57) 18 (11–45)
Data are n (%), median (range) for age in days, or median (interquartile range) for reciprocal antibody titers among seropositive participants. 
Baseline measurements for participants were obtained at 6 weeks of age.
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